Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 1/2013

01-02-2013 | Nephrology - Original Paper

Pre-transplant HbA1c level as an early marker for new-onset diabetes after renal transplantation

Authors: Erhan Tatar, Fatih Kircelli, Meltem Sezis Demirci, Mehmet Nuri Turan, Ozkan Gungor, Gulay Asci, Mehmet Ozkahya, Ercan Ok, Cuneyt Hoscoskun, Huseyin Toz

Published in: International Urology and Nephrology | Issue 1/2013

Login to get access

Abstract

Background

New-onset diabetes after transplantation (NODAT) is a common complication in renal transplant (RT) patients. The clinical significance of pre-transplant HbA1c level remains unclear in RT patients. Thus, we investigated the predictive role of pre-transplant HbA1c levels for the NODAT diagnosed in 1 year after renal transplantation.

Methods

Two hundred and four RT patients older than 18 years were analyzed. NODAT diagnosis during the 1-year follow-up after RT was based on the 2003 modified criteria of the ADA. HbA1c level was measured at pre-transplantation period and every 3 months after RT.

Results

Mean age was 39.3 ± 10.7 (20–73) years and 36 % were female. Mean pre-transplant HbA1c level was 4.9 ± 0.5 % (4.0–6.4 %). Pre-transplant HbA1c level was positively correlated with age, pre-transplant body mass index (BMI) and cholesterol level. Fifty-four patients (25.9 %) developed NODAT and 33.8 % had impaired fasting blood glucose levels. Patients with NODAT were significantly older and had higher pre-transplant BMI and HbA1c than those without. Use of Tacrolimus was also higher in patients with NODAT. In stepwise logistic regression analysis, pre-transplant HbA1c level was an independent predictor for the development on NODAT (OR = 4.63, 95 % CI: 2.09–10.2, p < 0.001) together with age, Tacrolimus-based regimen and pre-transplant fasting blood glucose level.

Conclusions

Assessment of pre-transplant HbA1c levels may be a valuable tool for early diagnosis of NODAT in RT recipients.
Literature
1.
Kasiske BL, Snyder JJ, Gilbertson D et al (2003) Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3(2):178–185PubMedCrossRef
2.
Demirci MS, Toz H, Yilmaz F et al (2010) Risk factors and consequences of post-transplant diabetes mellitus. Clin Transplant 24(5):170–177CrossRef
3.
Woodward RS, Schnitzler MA, Baty J (2003) Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 3(5):590–598PubMedCrossRef
4.
Ojo AO (2006) Cardiovascular complications after renal transplantation and their prevention. Transplantation 82(5):603–611PubMedCrossRef
5.
Hjelmesaeth J, Hartmann A, Leivestad T et al (2006) The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 69(3):588–595PubMedCrossRef
6.
Cosio FG, Pesavento TE, Kim S et al (2002) Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 62(4):1440–1446PubMedCrossRef
7.
Cosio FG, Kudva Y, van der Velde M et al (2005) New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 67(6):2415–2421PubMedCrossRef
8.
Boudreaux JP, McHugh L, Canafax DM et al (1987) The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 44(3):376–381PubMedCrossRef
9.
Sharif A, Baboolal K (2010) Risk factors for new-onset diabetes after kidney transplantation. Nat Rev Nephrol 6(7):415–423PubMedCrossRef
10.
Pham PT, Pham PM, Pham SV et al (2011) New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes 4:175–186PubMedCrossRef
11.
Dunn PJ, Cole RA, Soeldner JS et al (1979) Reproducibility of hemoglobin AIc and sensitivity to various degrees of glucose intolerance. Ann Intern Med 91(3):390–396PubMed
12.
International Expert Committee (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32(7):1327–1334CrossRef
13.
Saudek CD, Herman WH, Sacks DB et al (2008) A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 93(7):2447–2453PubMedCrossRef
14.
Ginde AA, Cagliero E, Nathan DM et al (2008) Value of risk stratification to increase the predictive validity of HbA1c in screening for undiagnosed diabetes in the US population. J Gen Intern Med 23(9):1346–1353PubMedCrossRef
15.
Hoban R, Gielda B, Temkit M et al (2006) Utility of HbA1c in the detection of subclinical post renal transplant diabetes. Transplantation 81(3):379–383PubMedCrossRef
16.
Valderhaug TG, Jenssen T, Hartmann A et al (2009) Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 88(3):429–434PubMedCrossRef
17.
The expert committee on the diagnosis and classification of diabetes mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26:5–20CrossRef
18.
Danaei G, Finucane MM, Lu Y et al (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378(9785):31–40PubMedCrossRef
19.
Pirsch JD, Miller J, Deierhoi MH et al (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63(7):977–983PubMedCrossRef
20.
van Duijnhoven EM, Christiaans MH, Boots JM et al (2002) Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 13(1):213–220PubMed
21.
Boots JM, van Duijnhoven EM, Christiaans MH et al (2002) Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 13(1):221–227PubMed
22.
Ishimura E, Okuno S, Kono K et al (2009) Glycemic control and survival of diabetic hemodialysis patients—importance of lower hemoglobin A1C levels. Diabetes Res Clin Pract 83(3):320–326PubMedCrossRef
23.
Perry RC, Shankar RR, Fineberg N et al (2001) HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with non-diagnostic levels of fasting plasma glucose. Diabetes Care 24(3):465–471PubMedCrossRef
24.
Kim KS, Kim SK, Lee YK et al (2008) Diagnostic value of glycated haemoglobin HbA(1c) for the early detection of diabetes in high-risk subjects. Diabet Med 25(8):997–1000PubMedCrossRef
25.
Rigalleau V, Gin H (2005) Carbohydrate metabolism in uraemia. Curr Opin Clin Nutr Metab Care 8(4):463–469PubMedCrossRef
26.
Chen J, Muntner P, Hamm LL et al (2003) Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14(2):469–477PubMedCrossRef
27.
Shaw JE, Hodge AM, de Courten M et al (1999) Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42(9):1050–1054PubMedCrossRef
28.
Hanefeld M, Fischer S, Julius U et al (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39(12):1577–1583PubMedCrossRef
29.
Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26(3):881–885PubMedCrossRef
30.
Ramesh Prasad GV, Huang M, Bandukwala F et al (2009) Pre-transplantation glucose testing for predicting new-onset diabetes mellitus after renal transplantation. Clin Nephrol 71(2):140–146PubMed
31.
Nam JH, Mun JI, Kim SI et al (2001) Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 71(10):1417–1423PubMedCrossRef
32.
Bergrem HA, Valderhaug TG, Hartmann A et al (2010) Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol 5(4):616–622PubMedCrossRef
33.
Caillard S, Eprinchard L, Perin P et al (2011) Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 91(7):757–764PubMed
34.
Peters AL, Davidson MB, Schriger DL et al (1996) A clinical approach for the diagnosis of diabetes mellitus. An analysis using glycosylated hemoglobin levels. JAMA 276(15):1246–1252PubMedCrossRef
35.
Dheir H, Ozkahya M, Kircelli F et al (2012) Glycosylated hemoglobin levels are associated with cardiovascular events in nondiabetic peritoneal dialysis patients. J Nephrol 25(1):107–112PubMedCrossRef
Metadata
Title
Pre-transplant HbA1c level as an early marker for new-onset diabetes after renal transplantation
Authors
Erhan Tatar
Fatih Kircelli
Meltem Sezis Demirci
Mehmet Nuri Turan
Ozkan Gungor
Gulay Asci
Mehmet Ozkahya
Ercan Ok
Cuneyt Hoscoskun
Huseyin Toz
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 1/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0304-z

Other articles of this Issue 1/2013

International Urology and Nephrology 1/2013 Go to the issue

Nephrology – Original Paper

Severe acute hypophosphatemia during renal replacement therapy adversely affects outcome of critically ill patients with acute kidney injury

Nephrology - Original Paper

Ethnic differences in 25-hydroxyvitamin D levels and response to treatment in CKD

Urology - Original Paper

The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term

Nephrology - Translational Section

Podocytes proliferate: novel mechanism identified in collapsing glomerulopathies

Urology - Original Paper

Detection and management of renal cell carcinoma in the renal allograft

Urology - Case Report

Neonatal urinary ascites complicated by ileal perforation in a recipient of twin-to-twin transfusion syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits